Docking Study of Licensed Non-Viral Drugs to Obtain Ebola Virus Inhibitors

Due to the power and high prevalence of infection and the lack of suitable medicine for the Ebola virus, research has been conducted on the discovery and introduction of anti-Ebola drugs. The purpose of the present study was to investigate the bioinformatic inhibition of Ebola virus entry and proliferation by licensed non-viral drugs. This research is a descriptive-analytical method and to carry out this investigation, first, the chemical structure of the compounds was drawn using ChemDraw Ultra 10.0 software, and then it was transferred to Hyperchem8 software to optimize the energy. Docking studies were carried out by AutoDock4.2 software and were analyzed in the final stage. The results obtained from the present study showed that the bonds involved in drug binding with receptors are hydrophobic, ?-?, hydrogen bonds, and cation-?. Among all studied compounds, the best docking results were related to chloroquine, diphenoxylate, and amodiaquine drugs. These three drugs with the most negative binding energy level had a greater tendency to bind to the amino acids of the binding site of GP and VP40 proteins. The weakest docking results were related to the two drugs erythromycin and dirithromycin, because the hydrophilicity of these two drugs is very high. In general, the presence of hydrophobic parts, optimal hydrogen bonds, and tertiary amine increases the anti-Ebola potency of drugs. Based on the results obtained from bioinformatics studies, all drugs show good inhibitory effects in the receptor binding site and can be considered effective inhibitors of Ebola virus entry and proliferation.

Progress in role of Niemann-Pick C1 protein in Ebola virus infection and its targeted drugs / 中国药理学与毒理学杂志

Ebola viruses belong to the Filoviridae family,which is highly contagious and likely to cause a variety of symptoms,including severe haemorrhagic fever in humans and primates,with a case fatality rate of up to 90%.Niemann-Pick C1(NPC1)protein is an important receptor expressed in the endosomal membrane of host cells during Ebola virus infection,and its interaction with the glycoprotein(GP)cleaved by cathepsin of Ebola virus is a key link in the viral infection host,mediating the fusion of the viral envelope and endosomal membrane before releasing the viral genome to the host cell.Recent years have seen some small molecule inhibitors and monoclonal antibody gene therapy drugs devel-oped by using NPC1 protein as a target of broad-spectrum anti-filovirus drugs.This article introduces the structure of NPC1 and its role in Ebola virus infection,and summarizes small molecule inhibitors,monoclonal antibody drugs and gene therapy drugs targeting NPC1.

Ebola virus disease: a zoonotic disease with an extremely high fatality rate / 中国热带医学

@# Ebola virus disease (EVD) is a severe infectious disease caused by Ebola virus in humans and primates. The main clinical features are fever and bleeding. The disease was first identified in Zaire and Sudan in Africa in 1976. Since then, it has caused many large-scale epidemics in Africa. One of the largest and most complex Ebola outbreaks in history was the 2014-2016 outbreak in West Africa, which caused more cases and deaths than all previous outbreaks combined. As of 2022, about 35 000 EVD cases and 15 000 deaths have been reported. During the African pandemic, EVD also spread to other regions outside the African continent, such as the Americas and Europe, and became a public health issue of worldwide concern. In Africa, the re-emergence of the disease in Uganda and the Republic of Congo in 2022 has attracted much attention from the world. This article systematically summarizes the history, epidemiological distribution, route of infection, clinical symptoms, diagnosis, treatment, prevention and control of Ebola virus disease, so as to provide reference for relevant workers in China.

Global Epidemic of Ebola Virus Disease and the Importation Risk into China: An Assessment Based on the Risk Matrix Method / 生物医学与环境科学（英文）

OBJECTIVE@#To analyze the global epidemic status of the Ebola virus disease (EVD) and assess the importation risk into China.@*METHODS@#Data from World Health Organization reports were used. We described the global epidemic status of EVD from 1976-2021, and assessed and ranked the importation risk of EVD from the disease-outbreaking countries into China using the risk matrix and Borda count methods, respectively.@*RESULTS@#From 1976-2021, EVD mainly occurred in western and central Africa, with the highest cumulative number of cases (14,124 cases) in Sierra Leone, and the highest cumulative fatality rate (85%) in the Congo. Outbreaks of EVD have occurred in the Democratic Republic of the Congo and Guinea since 2018. The importation risk into China varies across countries with outbreaks of disease. The Democratic Republic of the Congo had an extremely high risk (23 Borda points), followed by Guinea and Liberia. Countries with a moderate importation risk were Nigeria, Uganda, Congo, Sierra Leone, Mali, and Gabon, while countries with a low importation risk included Sudan, Senegal, and Co

Points of entry dynamics: understanding the cross-border threats for Ebola virus disease and COVID-19 in Ghana using a logic model approach

Background. The influx of people across the national borders of Ghana has been of interest and concern in the public health and national security community in recent times due to the low capacity for the prevention and management of epidemics and other public health risks. Although the International Health Regulations (IHR) stipulate core public health capacities for designated border facilities such as international airports, seaports, and ground crossings, contextual factors that influence the attainment of effective public health measures and response capabilities remain understudied. Objective. To assess the relationship between contextual factors and COVID-19 procurement to help strengthen infrastructure resources for points of entry (PoE) public health surveillance functions, thereby eliminating gaps in the design, implementation, monitoring, and evaluation of pandemicrelated interventions in Ghana. Materials and Methods. This study employed a mixed-methods design, where quantitative variables were examined for relationships and effect size interactions using multiple linear regression techniques and the wild bootstrap technique. Country-level data was sourced from multiple publicly available sources using the social-ecological framework, logic model, and IHR capacity monitoring framework. The qualitative portion included triangulation with an expert panel to determine areas of convergence and divergence. Results. The most general findings were that laboratory capacity and KIA testing center positively predicted COVID-19 procurement, and public health response and airline boarding rule negatively predicted COVID-19 procurement. Conclusion. Contextual understanding of the COVID-19 pandemic and Ebola epidemic is vital for strengthening PoE mitigation measures and preventing disease importation.

The two-stage interaction of Ebola virus VP40 with nucleoprotein results in a switch from viral RNA synthesis to virion assembly/budding

Ebola virus (EBOV) is an enveloped negative-sense RNA virus and a member of the filovirus family. Nucleoprotein (NP) expression alone leads to the formation of inclusion bodies (IBs), which are critical for viral RNA synthesis. The matrix protein, VP40, not only plays a critical role in virus assembly/budding, but also can regulate transcription and replication of the viral genome. However, the molecular mechanism by which VP40 regulates viral RNA synthesis and virion assembly/budding is unknown. Here, we show that within IBs the N-terminus of NP recruits VP40 and is required for VLP-containing NP release. Furthermore, we find four point mutations (L692A, P697A, P698A and W699A) within the C-terminal hydrophobic core of NP result in a stronger VP40-NP interaction within IBs, sequestering VP40 within IBs, reducing VP40-VLP egress, abolishing the incorporation of NC-like structures into VP40-VLP, and inhibiting viral RNA synthesis, suggesting that the interaction of N-terminus of NP with VP40 induces a conformational change in the C-terminus of NP. Consequently, the C-terminal hydrophobic core of NP is exposed and binds VP40, thereby inhibiting RNA synthesis and initiating virion assembly/budding.

Recent advances in the discovery and development of Ebola virus inhibitors / 药学学报

Ebola virus is extremely virulent and highly contagious. Ebola virus causes outbreaks of severe hemorrhagic fever, with human mortality rates of up to 90%. There is currently no preventive or therapeutic treatment in the form of vaccines, biological or small molecular agents. Currently, a lot of anti-Ebola virus agents have been reported. Here, we review the latest advances in this field.

Caracterización clínico epidemiológica de pacientes con ébola en un centro de tratamiento de Sierra Leona / Clinical-epidemiological characterization of Ebola disease in patients at a treatment center in Sierra Leone

Introducción: La enfermedad del ébola se dio a conocer por primera vez en 1976, con una letalidad muy elevada en todos los brotes detectados. Objetivo: Caracterizar clínica y epidemiológicamente a los pacientes portadores de la enfermedad por el virus del Ébola. Métodos: Se realizó un estudio observacional, descriptivo y transversal en 424 pacientes ingresados en un centro de tratamiento de ébola en la República de Sierra Leona, África occidental, con el diagnóstico confirmado mediante la técnica de reacción en cadena de la polimerasa para virus Ébola, durante el período de noviembre de 2014 hasta marzo de 2015. Resultados: Se muestra que el grupo etario más afectado fue el de 25 a 34 con un 25,9 por ciento. La mayor letalidad se presentó en los pacientes con más de 65 años de edad con un 44,4 por ciento. El síntoma que prevaleció fue la fiebre para un 61,8 por ciento, y el hipo se presentó en el 88,8 por ciento de los fallecidos. Conclusión: Se concluye que la enfermedad no tuvo distinción significativa con el sexo. La mayor letalidad se presentó en las edades geriátricas. Los síntomas más frecuentes fueron la fiebre, diarrea y el decaimiento. El hipo fue el signo que más se presentó en los pacientes que fallecieron(AU)

Introduction: Ebola disease was first reported in 1976 with a very high lethality in all outbreaks. Objective: To clinically and epidemiologically characterize the patients carriers of Ebola virus disease. Methods: we conducted an observational, descriptive and cross-sectional study in 424 patients admitted to an Ebola Treatment Center in the Republic of Sierra Leone, West Africa from November 2014 to March 2015. The polymerase chain reaction technique for Ebola virus confirmed the diagnosis. Medical records provided all data. Results: The age group most affected was 25 to 34 (25.9 percent). The highest lethality occurred in those over 65 years of age (44.4 percent ). Fever was the prevailing symptom (61.8 percent) and hiccups occurred in 88.8 percent of the deceased. Conclusion: Clinical manifestations were variable, although fever was the main symptom. Hiccup was a sign of poor prognosis when associated with a higher percentage of mortality. Lethality was high(AU)

Ebola virus disease: Recent advancs in diagnostics and therapeutics

Ebola virus disease (EVD) is associated with haemorrhagic fever in humans and nonhuman primates, with a high rate of fatality (up to 90%). Some outbreaks in human history have proven the lethality of EVD. The recent epidemic of 2014 and 2015 in West Africa was the deadliest of all time (11 284 deaths). To understand the transmission dynamics, we have reviewed the epidemiology of EVD to date. The absence of any licensed vaccines or approved drugs against Ebola virus (EBOV) further highlights the severity and crisis level of EVD. Some organizations (public and private) are making considerable efforts to develop novel therapeutic approaches or vaccines to contain the outbreak of EBOV shortly. Here, we summarized the various potential drugs and vaccines (undergoing multiple phases of clinical trials) that have arisen as an alternative against EBOV, and we highlighted the numerous issues and limitations hindering this process. Alternatively, an increasing focus on strengthening the medical and civic health structure could provide speedy benefits in containing the spread of EVD, as well as offer a resilient foundation for the deployment of novel drugs and vaccines to the affected countries, once such drugs and vaccines become available.

Ebola virus disease: Recent advancs in diagnostics and therapeutics

Ebola virus disease (EVD) is associated with haemorrhagic fever in humans and nonhuman primates, with a high rate of fatality (up to 90%). Some outbreaks in human history have proven the lethality of EVD. The recent epidemic of 2014 and 2015 in West Africa was the deadliest of all time (11 284 deaths). To understand the transmission dynamics, we have reviewed the epidemiology of EVD to date. The absence of any licensed vaccines or approved drugs against Ebola virus (EBOV) further highlights the severity and crisis level of EVD. Some organizations (public and private) are making considerable efforts to develop novel therapeutic approaches or vaccines to contain the outbreak of EBOV shortly. Here, we summarized the various potential drugs and vaccines (undergoing multiple phases of clinical trials) that have arisen as an alternative against EBOV, and we highlighted the numerous issues and limitations hindering this process. Alternatively, an increasing focus on strengthening the medical and civic health structure could provide speedy benefits in containing the spread of EVD, as well as offer a resilient foundation for the deployment of novel drugs and vaccines to the affected countries, once such drugs and vaccines become available.

Memorias de un enfermero cubano cara a cara con el Ébola en Guinea Conakry / Memories of a Cuban Nurse face to face with Ebola in Guinea Conakry

Introducción: La enfermedad ocasionada por el virus Ébola ha sido la peor epidemia en África Occidental entre 2014 y 2015, se infectaron más de 27 000 personas, con más de 11 000 muertes en Guinea, Liberia y Sierra Leona. Cuba fue de los primeros países del mun do en dar respuesta al llamado de la Organización Mundial de la Salud y la Organización de Naciones Unidas para enfrentar la epidemia en los países afectados, enviando 256 profesionales Médicos y Enfermeros del Contingente Internacional "Henry Reeve". Objetivo: Exponer la experiencia de un enfermero cubano en el enfrentamiento de la epidemia del virus Ébola en África Occidental. Métodos: La investigación se realizó desde una perspectiva cualitativa, a fin de poner exponer las experiencias vividas por los colaboradores de la Brigada Médica Cubana "Henry Reeve" que enfrentaron la epidemia de Ébola en Guinea Conakry desde octubre de 2014 hasta mayo de 2015. Conclusiones: Los colaboradores regresaron con la satisfacción del deber cumplido, con cero casos confirmados de Ébola en el Centro de tratamiento y en la prefectura de Coyah, se concluyó la misión con una evaluación satisfactoria(AU)

Introduction: The Ebola virus disease has been the worst epidemic in West Africa between 2014 and 2015, more than 27 000 people were infected, with more than 11 000 deaths in Guinea, Liberia and Sierra Leone. Cuba was one of the first countries worldwide to respond to the call of the World Health Organization and the United Nations to confront the epidemic in the affected countries, sending 256 medical professionals and nurses of Henry Reeve International Contingent. Objective: To present a Cuban nurse's experience in confronting the Ebola virus epidemic in West Africa. Methods: The research was conducted from a qualitative perspective, in order to expose the experiences lived by the collaborators of Henry Reeve Cuban Medical Brigade, who confronted the Ebola epidemic in Guinea Conakry from October 2014 to May 2015. Conclusions: The collaborators returned with the satisfaction of the duty fulfilled, with zero confirmed cases of Ebola in the Treatment Center and in the Coyah prefecture; the mission was concluded with a satisfactory evaluation(AU)

Mathematical Modeling and Optimal Control of Ebola Virus Disease (EVD)

In this paper, a nonlinear mathematical model is developed and analyzed to study the dynamics of Ebola virus (EVD) and the effects of some control strategies. The model validity is investigated and was found to be locally asymptotically stable when the basic reproduction number  and unstable otherwise. Pontryagin's maximum principle is applied to obtain the optimality conditions. Numerical simulation was carried out and the results obtained indicate that a combination of all three control parameters is highly effective in containing the spread of the virus.

Neutralizing Antibody Titer Test of Ebola Recombinant Protein Vaccine and Gene Vector Vaccine pVR-GP-FC / 生物医学与环境科学（英文）

<p><b>OBJECTIVE</b>In previous studies, we immunized mice with Ebola recombinant protein vaccine and gene vector vaccine. Both stimulated high levels of humoral immunity. In this work, we constructed a pseudovirus containing Ebola membrane proteins to verify whether the two immunization strategies can induce neutralizing antibodies in mice.</p><p><b>METHODS</b>A pseudovirus containing an Ebola virus membrane protein based on the HIV-1 viral gene sequence was constructed and evaluated using a known neutralizing antibody. The titer of the neutralizing antibody in the sera of mice immunized with the recombinant protein and the gene vector vaccine was examined using a neutralization test.</p><p><b>RESULTS</b>Ebola pseudovirus was successfully prepared and applied for neutralizing antibody detection. Immunological experiments showed that recombinant protein GP-Fc and gene vaccine pVR-modGP-Fc had good immunogenicity. The titer of the bound antibody in the serum after 8 weeks of immunization in mice was more than 1:105, and the recombinant protein induced greater humoral immunity. The results of the neutralization test based on the Ebola pseudovirus system demonstrated that both vaccines induced production of protective antibodies, while the gene vaccine induced a higher titer of neutralizing antibodies.</p><p><b>CONCLUSION</b>An Ebola pseudovirus detection system was successfully established and used to evaluate two Ebola vaccines. Both produced good immunogenicity. The findings lay the foundation for the development of new Ebola vaccines and screening for neutralizing monoclonal antibodies.</p>

A novel carbon nanoparticle probe-based ultrasensitive lateral flow assay for rapid detection of Ebola virus / 生物工程学报

Ebola virus (EBOV) is an extremely contagious pathogen first discovered in Africa associated with severe hemorrhagic disease in humans and nonhuman primates, which has resulted in at least 28 500 suspected cases and 11 300 confirmed deaths in 2014-2016 Ebola epidemic in West Africa. Rapid and sensitive detection of EBOV is the key to increasing the probability of survival and reducing infection rates in pandemic regions. Here, we report an ultrasensitive and instrument-free EBOV detection assay based on colloidal carbon immunochromatography. Carbon nanoparticle-labeled rabbit anti-EBOV-VP40 IgG were concentrated in the conjugate pad, monoclonal antibody (McAb, 4B7F9) against EBOV-VP40 and goat anti-rabbit IgG were immobilized on the nitrocellulose membrane with 2 μL/cm at a concentration of 1 mg/mL as test and control lines, respectively. Then the sample application pad, conjugate release pad, nitrocellulose membrane and absorbent pad were assembled into a lateral flow test strip. The test strip shows strong specificity against related viruses that share similar clinical symptoms and geographic range with EBOV, including marburg virus, influenza virus, yellow fever virus and dengue virus. In addition, 1 500 negative serums were tested with false-positive rate of 1.3‰ which significantly lower than that of ReEBOV™ colloidal gold test kit recommended by World Health Organization (WHO). The sensitivity of this strip was analyzed using inactivated EBOV with detection limit of 100 ng/mL (10⁶ copies/mL) which clearly higher than that of ReEBOV™ dipstick (10⁸ copies/mL). Furthermore, the strip showed excellent thermal stability characteristics in room temperature and could be as a point-of-care (POC), ultra-sensitive and specific promising candidate for EBOV serological screening in rural Africa or entry/exit ports.

Enfermedad por el virus Ébola medidas de bioseguridad / Ebola virus disease biosafety measures

Resumen El virus Ébola representa el patógeno prototipo de fiebre hemorrágica viral, causando una enfermedad severa de alta tasa de mortalidad. Esta alta mortalidad, combinada con la ausencia de vacunación y de un tratamiento específico, hace que el virus Ébola sea un patógeno importante para la salud pública. La fiebre hemorrágica de Ébola se cree es una zoonosis con persistencia del virus en especies de reservorios encontrados en áreas endémicas. A pesar de todos los esfuerzos realizados en cada brote para identificar los reservorios naturales no se conocen huéspedes potenciales ni los artrópodos vectores. El manejo de los casos está basado en el aislamiento de los pacientes y en el uso de barreras de aislamiento, tales como ropa e implementos de protección como respiradores. Debido a su rápida propagación la OMS declaró que la enfermedad por el virus Ébola representa una emergencia de salud pública más allá de las fronteras y exhortó a la comunidad internacional a tomar las acciones necesarias para detener la epidemia.

Abstract Ebola virus is regarded as the prototype pathogen of viral hemorrhagic fever, causing severe disease and high case fatality rates. This high fatality, combined with the absence ot treatment and vaccination options, makes Ebola virus an important public health pathogen. Ebola hemorrhagic fever is thought to be a classic zoonosis with persistence of the Ebola virus in a reservoir species generally found in endemic areas. Although much effort has been made to identify the natural reservoirs with every large outbreak of Ebola hemorrhagic fever, neither potential hosts norarthropod vectors have been identified. Case management is based on isolation of patients and use of strict barrier nursing procedures, such as protective clothing and respirators. In addition, its rapid propagation has led the Word Health Organization (WHO) to declare on August 2014 that Ebola virus disease represents a public health emergency of international concern and urged the international community to take action to stop its spread.

Enfermedad por el virus del Ébola en el Centro de Tratamiento Coyah / Ebola virus disease at the Coyah Treatment Center

Introducción: la enfermedad por Ébola tiene elevada letalidad y no existe tratamiento efectivo. Es necesario su estudio y estar preparados para el enfrentamiento de futuras epidemias. Objetivo: describir la distribución espacio-temporal y relación con variables de persona, lugar y tiempo, de los pacientes con la enfermedad por el virus del Ébola atendido en el Centro de Tratamiento de Coyah. Métodos: se realizó un estudio descriptivo transversal. El universo lo constituyó los pacientes ingresados (N= 350) en este centro. La información se obtuvo de las historias clínicas. Resultados: se confirmaron casos con Ébola 244 pacientes (69,71 por ciento de positividad), 53,28 por ciento del sexo femenino; la media de edades fue de 30 años; 5 días promedio entre el inicio de los síntomas y el ingreso (mediana de 4 días). El 90,57 por ciento de los enfermos procedía de la región Kindia y 61,07 por ciento de la prefectura Forecariah. El número de pacientes ingresados, según semana estadística, presentó las fluctuaciones características de los brotes epidémicos. En el centro se registraron 133 fallecidos (tasa de letalidad de 54,5 por cada 100 enfermos confirmados). Conclusiones: la elevada confirmación de casos caracterizó la enfermedad, presente fundamentalmente en mujeres jóvenes, con ingreso alrededor de una semana, a partir de los primeros síntomas. La incidencia semanal de casos presentó fluctuaciones características de brotes epidémicos. La tasa de letalidad de la enfermedad fue baja(AU)

Introduction: Ebola disease has a high lethality and there is no effective treatment. It is necessary to study it and be prepared for dealing of future epidemics. Objective: To describe the spatio temporal distribution and relationship with variables of person, place and time of the patients treated at the Ebola Treatment Center in Coyah. Methods: A cross-sectional descriptive study was carried out. The universe were the admitted patients (N= 350) in this Center. The information was obtained from the medical records. Results: Ebola cases were confirmed in 244 patients (69.71 percent positivity), 53.28 percent in females; the average age was 30 years; 5 days average between the onset of symptoms and admission (median of 5 days). 90.57 percent of the patients came from the Kindia Region and 61.07 percent from the Forecariah prefecture. The number of patients admitted, according to statistical week, presented the characteristic fluctuations of epidemic outbreaks. In the center there were 133 deaths (case fatality rate of 54.5 per 100 confirmed patients). Conclusions: The high confirmation of cases characterized the disease, present mainly in young women, with admission around the week, from the first symptoms. The weekly incidence of cases showed characteristic fluctuations of epidemic outbreaks. The case fatality rate was low(AU)

Preferential production of IgM-secreting hybridomas by immunization with DNA vaccines coding for Ebola virus glycoprotein: use of protein boosting for IgG-secreting hybridoma production

PURPOSE: The goal of this study was to investigate the utility of DNA vaccines encoding Ebola virus glycoprotein (GP) as a vaccine type for the production of GP-specific hybridomas and antibodies. MATERIALS AND METHODS: DNA vaccines were constructed to express Ebola virus GP. Mice were injected with GP DNA vaccines and their splenocytes were used for hybridoma production. Enzyme-linked immunosorbent assays (ELISAs), limiting dilution subcloning, antibody purification methods, and Western blot assays were used to select GP-specific hybridomas and purify monoclonal antibodies (MAbs) from the hybridoma cells. RESULTS: Twelve hybridomas, the cell supernatants of which displayed GP-binding activity, were selected by ELISA. When purified MAbs from 12 hybridomas were tested for their reactivity to GP, 11 MAbs, except for 1 MAb (from the A6-9 hybridoma) displaying an IgG2a type, were identified as IgM isotypes. Those 11 MAbs failed to recognize GP. However, the MAb from A6-9 recognized the mucin-like region of GP and remained reactive to the antigen at the lowest tested concentration (1.95 ng/mL). This result suggests that IgM-secreting hybridomas are predominantly generated by DNA vaccination. However, boosting with GP resulted in greater production of IgG-secreting hybridomas than GP DNA vaccination alone. CONCLUSION: DNA vaccination may preferentially generate IgM-secreting hybridomas, but boosting with the protein antigen can reverse this propensity. Thus, this protein boosting approach may have implications for the production of IgG-specific hybridomas in the context of the DNA vaccination platform. In addition, the purified monoclonal IgG antibodies may be useful as therapeutic antibodies for controlling Ebola virus infection.

Analysis with capability of responding to emerging infectious diseases among medical university students in Chongqing city / 重庆医学

Objective To take Ebola virus disease (EVD) as an example and analyze the capability of responding to emerging infectious diseases among medical university students in Chongqing city.Methods Medical university students of 2 094 in Chongqing were selected and investigated by cluster sampling.Questionnaire content includes social demographic information,knowledge,attitude,practice (KAP) and related factors about EVD.The variables of the respondents were described using mean and standard deviation for continuous variables and frequency distributions for categorical variables.Influencing factors were analyzed by using multiple-linear regression model.Results The average scores of KAP regarding EVD were 9.51 ±-3.97,5.93± 1.85,3.35 ±1.43,respectively.Multiple-linear regression analysis showed that the influencing factors of KAP regarding EVD were gender (x2 =0.773,P=0.000),residence (x2 =0.886,P=0.014) and health habits (x2 =0.316,P=0.008);gender (x2 =0.474,P=0.000),grade (x2 =0.118,P=0.024),residence (x2 =0.401,P=0.016) and health habits (x2 =0.307,P=0.000);gender (x2 =0.223,P=0.001),major (x2 =0.152,P=0.000) and health habits (x2 =0.231,P=0.000).Conclusion The capability of responding to emerging infectious diseases is not optimistic among medical university students.Medical universities should perform effective intervention according to the characters of different clusters.

An update on the 2014 Ebola outbreak in Western Africa

The recent Ebola outbreak in Western Africa was the most devastating outbreak witnessed in recent times. There have been remarkable local and international efforts to control the crisis. Ebola Virus Disease is the focus of immense research activity. The progression of events in the region has been evolving swiftly and it is of paramount importance to the medical community to be acquainted with the situation. Over 28000 people were inflicted with the condition, over 11000 have died. Novel data has emerged regarding modes of transmission, providing rationale for recent flare-ups. Similarly, studies on survivors are elucidating the later stages of the disease recovery process. Novel techniques for diagnosis are also discussed. Finally, the current research regarding treatment and vaccine development is reviewed, particularly the implementation of rVSV-ZEBOV vaccination programs.

Medical service and management of pregnant women during the Ebola epidemic / 中华实验和临床病毒学杂志

The Ebola epidemic occurrence during 2014-2016 is the largest-ever Ebola virus outbreak with an unprecedented scale and impact. The difficulties faced by pregnant women living within the epidemic area are complex and multi-factorial which merits our concern. In this review, we aimed to summarize some of the guidelines published by the World Health Organization during the outbreak, and to provide a broad overview of the issues that arise from pregnant women. Based on our own experience in Sierra Leone, we also made an analysis of the complex interaction between the Ebola virus disease, pregnancy, medical staff, public health systems and the society, and intended to afford peers useful information. The management strategies should be prepared in advance to against the potential epidemic threats and ensure the reliability of life-saving maternity services in China.